Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 3/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | DBH | P09172 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30364561 | 0.88 | HTR6 (0.50) | HTR6HTR2CHTR2AEGFRDBH | |
| SCHEMBL5134071 | 0.81 | HTR6 (0.66) | HTR6BRD4PLAUSLC2A1APP | |
| SCHEMBL396279 | 0.81 | HTR6 (0.66) | HTR6BRD4PLAUSLC2A1APP | |
| SCHEMBL6085996 | 0.79 | HTR6 (0.58) | HTR6HTR2CHTR2ADBHPLAU | |
| SCHEMBL31257980 | 0.79 | HTR6 (0.58) | HTR6HTR2CHTR2ADBHPLAU | |
| SCHEMBL710139 | 0.78 | HTR2A (0.55) | BRD4HTR2CHTR2A | |
| SCHEMBL6257025 | 0.77 | HDAC8 (0.48) | HTR6BRD4HTR2CHTR2APLAU | |
| SCHEMBL710538 | 0.77 | HTR6 (0.49) | HTR6BRD4HTR2CHTR2AEGFR | |
| SCHEMBL709684 | 0.76 | HTR7 (0.48) | BRD4DBHPLAUPPARG | |
| SCHEMBL2768186 | 0.75 | HTR6 (0.58) | HTR6HTR2CHTR2AEGFRPLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124647-B2 | Non-steroidal androgens compounds | N.V. ORGANON (NL) | 2012-02-28 | — | — | US | disclosed |
| US-20110065768-A1 | NON-STEROIDAL ANDROGENS COMPOUNDS | MERCK SHARP & DOHME B.V. (NL) | 2011-03-17 | — | — | US | disclosed |
| US-20110009428-A1 | NOVEL ANDROGENS | N.V. ORGANON (NL) | 2011-01-13 | — | — | US | disclosed |
| US-7812036-B2 | Androgens | N.V. ORGANON (NL) | 2010-10-12 | — | — | US | disclosed |
| US-7795280-B2 | Indoles useful in the treatment of androgen-receptor related diseases | N.V. ORGANON (NL) | 2010-09-14 | — | — | US | disclosed |
| EP-1742912-B1 | NOVEL ANDROGENS | ORGANON NV (NL) | 2010-08-25 | — | — | EP | disclosed |
| EP-1585727-B1 | INDOLES USEFUL IN THE TREATMENT OF ANDROGEN-RECEPTOR RELATED DISEASES | ORGANON NV (NL) | 2010-05-26 | — | — | EP | disclosed |
| US-20070225352-A1 | Novel Androgens | PHARMACOPELA DRUG DISCOVERY, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| EP-1742912-A1 | NOVEL ANDROGENS | N.V. Organon (NL) | 2007-01-17 | — | — | EP | disclosed |
| US-20060128722-A1 | Indoles useful in the treatment of androgen-receptor related diseases | AKZO NOBEL N.V. (NL) | 2006-06-15 | — | — | US | disclosed |
| WO-2005102998-A1 | NOVEL ANDROGENS | N.V. ORGANON (NL) | 2005-11-03 | — | — | WO | disclosed |
| EP-1585727-A1 | INDOLES USEFUL IN THE TREATMENT OF ANDROGEN-RECEPTOR RELATED DISEASES | Akzo Nobel N.V. (NL) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004041782-A1 | INDOLES USEFUL IN THE TREATMENT OF ANDROGEN-RECEPTOR RELATED DISEASES | AKZO NOBEL N.V. (NL) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225352-A1 | Novel Androgens | NR5A1, AR, SHBG | HTR6 734/4885BRD4 867/4885HTR2C 489/4885 |
| US-20110065768-A1 | NON-STEROIDAL ANDROGENS COMPOUNDS | AR, NR5A1, SHBG | HTR6 505/4885BRD4 1065/4885HTR2C 557/4885 |
| US-20060128722-A1 | Indoles useful in the treatment of androgen-receptor related diseases | AR, NR5A1, SHBG | HTR6 155/4885BRD4 743/4885HTR2C 190/4885 |
| US-20110009428-A1 | NOVEL ANDROGENS | NR5A1, AR, NR3C2 | HTR6 209/4885BRD4 688/4885HTR2C 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.